Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study

Abstract

Our study demonstrates that subcutaneous anti-TNF-α agents are appropriate in the long-term management of elderly patients.